1. Home
  2. XYL vs RMD Comparison

XYL vs RMD Comparison

Compare XYL & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xylem Inc. New

XYL

Xylem Inc. New

HOLD

Current Price

$138.72

Market Cap

36.7B

Sector

Industrials

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$245.15

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYL
RMD
Founded
2011
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.7B
36.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
XYL
RMD
Price
$138.72
$245.15
Analyst Decision
Buy
Buy
Analyst Count
9
13
Target Price
$161.33
$289.09
AVG Volume (30 Days)
1.3M
939.4K
Earning Date
02-03-2026
01-29-2026
Dividend Yield
1.15%
0.98%
EPS Growth
13.52
29.59
EPS
3.88
9.77
Revenue
$8,894,000,000.00
$5,257,400,000.00
Revenue This Year
$6.53
$9.85
Revenue Next Year
$3.71
$7.36
P/E Ratio
$35.76
$25.02
Revenue Growth
5.58
9.36
52 Week Low
$100.48
$199.92
52 Week High
$154.27
$293.81

Technical Indicators

Market Signals
Indicator
XYL
RMD
Relative Strength Index (RSI) 45.11 43.12
Support Level $136.32 $241.66
Resistance Level $139.72 $247.45
Average True Range (ATR) 2.12 4.94
MACD 0.37 -0.28
Stochastic Oscillator 53.56 18.66

Price Performance

Historical Comparison
XYL
RMD

About XYL Xylem Inc. New

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: